The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / A•••• R•• I•••

C••••••••• Advises A•••• in its Acquisition by D••••••• H•••••

Add-on acquisitionannouncedadd-onannounced Sep 9, 2026Fact
What happened
Target
A•••• R•• I•••
Platform
D••••••• H•••••• I•••add-on basis: C••••••••• served as the exclusive sell-side advisor to A•••• R•• I••• (the "Company" or "A••••") on its acquisition by D••••••• H•••••• I••• ("D•••••••"), a portfolio company of A•••• Partners ("A••••").
Control
Control
Share acquired
unknown
Industry
technology / technology
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
6 named
Buy side
  • D••••••• H•••••• I•••Platformconfirmed
    “C••••••••• served as the exclusive sell-side advisor to A•••• R•• I••• (the "Company" or "A••••") on its acquisition by D••••••• H•••••• I••• ("D•••••••"), a portfolio company of A•••• Partners ("A••••").”
  • A•••• P••••••• L••Sponsorconfirmed
    “C••••••••• served as the exclusive sell-side advisor to A•••• R•• I••• (the "Company" or "A••••") on its acquisition by D••••••• H•••••• I••• ("D•••••••"), a portfolio company of A•••• Partners ("A••••").”
Advisory side
  • C••••••••• A•••••••• I•••Sell-side adviserconfirmed
    “C••••••••• Advises A•••• in its Acquisition by D••••••• H•••••”
Side not stated
  • N•• K•••••••Managementconfirmed
    “N•• K•••••••, Co-Founder and Chief Commercial Officer of A••••, commented, "This partnership represents an exciting opportunity to expand the value we deliver to life sciences organizations serving rare and specialty disease populations.”
  • R•• S•••••••Managementconfirmed
    “R•• S•••••••, Co-Founder and Chief Executive Officer of A••••, added, "As we evaluated opportunities to support A••••'s continued growth, it was important to find a partner that shared our vision for helping life sciences organizations better serve patients with rare and specialty diseases.”
  • A•••• R•• I•••Targetconfirmed
    “C••••••••• served as the exclusive sell-side advisor to A•••• R•• I••• (the "Company" or "A••••") on its acquisition by D••••••• H•••••• I••• ("D•••••••"), a portfolio company of A•••• Partners ("A••••").”
Evidence
“C••••••••• served as the exclusive sell-side advisor to A•••• R•• I••• (the "Company" or "A••••") on its acquisition by D••••••• H•••••• I••• ("D•••••••"), a portfolio company of A•••• Partners ("A••••").”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026
C••••••••• Advises A•••• in its Acquisition by D••••••• H••••• | Private Equity Intelligence | DFX